Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study

書誌詳細
主要な著者:	Nash, P, Coates, L, Kivitz, A, Mease, P, Gladman, D, Covarrubias-Cobos, J, Fleishaker, D, Wang, C, Kudlacz, E, Menon, S, Fallon, L, Hendrikx, T, Kanik, K
フォーマット:	Conference item
出版事項:	BMJ Publishing Group Limited 2018

Safety and efficacy of Tofacitinib, an oral Janus Kinase inhibitor, up to 36 Months in patients with active Psoriatic Arthritis: data from the third interim analysis of OPAL balance, an Open-Label, long-term extension study
著者:: Nash, P, 等
出版事項: (2018)

Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
著者:: Peter Nash, 等
出版事項: (2020-06-01)

Safety and efficacy of Tofacitnib in patients with active psoriatic arthritis: Interim analysis of OPAL balance, an open-label, long-term extension study
著者:: Nash, P, 等
出版事項: (2020)

Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study
著者:: Nash, P, 等
出版事項: (2021)

Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance
著者:: Nash, P, 等
出版事項: (2020)

Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond
著者:: Philip J Mease, 等
出版事項: (2019-06-01)

Tofacitinib improves composite endpoint measures of disease in patients with psoriatic arthritis
著者:: Helliwell, P, 等
出版事項: (2018)

Efficacy of tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two phase 3 studies
著者:: Nash, P, 等
出版事項: (2018)

Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease
著者:: Helliwell, P, 等
出版事項: (2018)

Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies
著者:: Peter Nash, 等
出版事項: (2018-11-01)

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
著者:: Philip J Mease, 等
出版事項: (2019-06-01)

Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease
著者:: Philip Helliwell, 等
出版事項: (2018-10-01)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
著者:: Gladman, DD, 等
出版事項: (2022)

Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
著者:: Philip J. Mease, 等
出版事項: (2024-01-01)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in Phase 3 studies of tofacitinib
著者:: Coates, L, 等
出版事項: (2021)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
著者:: Dafna D. Gladman, 等
出版事項: (2022-02-01)

Median time to pain improvement in patients with psoriatic arthritis treated with tofacitinib
著者:: de Vlam, K, 等
出版事項: (2018)

Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis
著者:: Dafna D. Gladman, 等
出版事項: (2024-12-01)

Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies
著者:: Ana-Maria Orbai, 等
出版事項: (2022-09-01)

Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies
著者:: Philip J. Mease, 等
出版事項: (2023-08-01)

Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib
著者:: Lars E. Kristensen, 等
出版事項: (2023-02-01)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib
著者:: Laura C. Coates, 等
出版事項: (2021-03-01)

Understanding mediators of pain reduction in psoriatic arthritis patients treated with tofacitinib: role of inflammation
著者:: Taylor, P, 等
出版事項: (2019)

Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by Cigarette Smoking Status
著者:: Alexis Ogdie, 等
出版事項: (2024-09-01)

The effect of tofacitinib on residual pain in patients with psoriatic arthritis
著者:: Dougados, M, 等
出版事項: (2020)

Baseline pain severity as a predictor of pain improvement following treatment with tofacitinib in psoriatic arthritis
著者:: Ogdie, A, 等
出版事項: (2018)

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
著者:: Dougados, M, 等
出版事項: (2022)

Risk Stratification of Patients with Psoriatic Arthritis and Ankylosing Spondylitis for Treatment with Tofacitinib: A Review of Current Clinical Data
著者:: Lars Erik Kristensen, 等
出版事項: (2024-05-01)

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
著者:: Maxime Dougados, 等
出版事項: (2022-11-01)

Identifying and quantifying the role of inflammation in pain reduction for patients with psoriatic arthritis treated with tofacitinib: a mediation analysis
著者:: de Vlam, K, 等
出版事項: (2022)

Tofacitinib Reduces Spinal Inflammation in Vertebral Bodies and Posterolateral Elements in Ankylosing Spondylitis: Results from a Phase 2 Trial
著者:: Mikkel Østergaard, 等
出版事項: (2023-06-01)

Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib
著者:: de Vlam, K, 等
出版事項: (2021)

Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis
著者:: Ogdie, A, 等
出版事項: (2023)

Psoriatic arthritis - Tofacitinib as a new treatment
著者:: Marta Skorupska, 等
出版事項: (2024-06-01)

Post-marketing safety surveillance of tofacitinib over 9 years in patients with psoriatic arthritis and rheumatoid arthritis
著者:: Burmester, GR, 等
出版事項: (2023)

Identifying mediators of pain reduction in patients with psoriatic arthritis treated with tofacitinib: Role of inflammation associated with peripheral arthritis, enthesitis and skin disease
著者:: Taylor, PC, 等
出版事項: (2020)

Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis
著者:: Dafna D. Gladman, MD, 等
出版事項: (2020-01-01)

Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
著者:: Gerd R. Burmester, 等
出版事項: (2023-07-01)

Insights into the Binding Recognition and Susceptibility of Tofacitinib toward Janus Kinases
著者:: Kamonpan Sanachai, 等
出版事項: (2020-01-01)

The benefits and challenges of setting up a longitudinal psoriatic arthritis database
著者:: Gladman, DD, 等
出版事項: (2018)

Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study

類似資料

類似資料